Campaigners protest former EMA chief's private sector roles
Campaigners have sent a letter to European Health Commissioner John Dalli taking issue with the European Medicines Agency's decision to allow its former executive director Thomas Lonngren to take up an advisory role within the pharmaceutical industry within weeks of leaving the agency.
Lonngren left the EMA at the end of December 2010 to join the NDA Advisory Services, a regulatory and market access consultancy, as well as various other roles within the pharmaceutical industry.
The letter- sent jointly by the Alliance for Lobby Transparency and Ethics Regulation (ALTER-EU), the European Consumers’ Organisation (BEUC), the European Public Health Alliance (EPHA), Health Action International Europe (HAI), and the International Society of Drug Bulletins (ISDB) - suggests that EMA rules regarding conflicts of interest may not have been respected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze